NCT04875611

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Phase II Study Evaluating the Efficacy of Nivolumab in the Treatment of Patients With Nasopharyngeal Cancer Who Progressed During or After Platinum-based Chemotherapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.

Conditions

• Nasopharyngeal Cancer

Interventions

Type	Name	Description
DRUG	Opdivo	Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).

Timeline

• Start date: 2021-08-26
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2021-05-06
• Last updated: 2025-04-24

Locations

4 sites across 1 country: Poland